<DOC>
	<DOCNO>NCT02699879</DOCNO>
	<brief_summary>This single arm , post-authorisation study design evaluate long-term safety pirfenidone participant IPF . The enrolment participant complete within approximately 24 month . Participants receive pirfenidone accord physician discretion follow 2 year . Treating physician collect pre-specified data baseline every 3 month thereafter , duration participant ' participation study .</brief_summary>
	<brief_title>Evaluation Long-Term Safety Pirfenidone ( Esbriet ) Participants With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>A clinical decision make , prior study enrolment , prescribe pirfenidone Participants newly prescribe pirfenidone therapy Initiation pirfenidone therapy 30 day prior study enrolment Participants receive investigational agent define drug approve marketing indication country participate site Participant receive Esbriet therapy 30 day prior current treatment course ( e.g. , prior participation clinical trial ) Participant contraindication use Esbriet , accord current local version Summary Product Characteristics ( SPC )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>